To further assess the impact of concurrent metabolic co-morbidities on prevalence of advanced fibrosis among individuals with NASH, we specifically focused on the subset of NAFLD/NASH ICD-9/10 cohort and calculated the prevalence of F3/F4 fibrosis in patients with elevated ALT and incremental increasing number of concurrent metabolic co-morbidities (Fig 2). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.